Exelixis (EXEL) news
Recent news
Exelixis Inc: RBC raises target price to $51 from $45
RBC Capital Markets has raised its price target for Exelixis Inc (NASDAQ: EXEL) to $51 from $45, reflecting a more optimistic outlook on the biopharmaceutical company’s near-term prospects. The adjustment follows recent developments in Exelixis’ pipeline and ongoing clinical trials, particularly…
AInvest Wire · 5d agoExelixis Inc: RBC cuts target price to $45 from $46
RBC Capital has lowered its target price for Exelixis Inc. (NASDAQ:EXEL) to $45 from $46, reflecting a recent adjustment in the firm’s outlook for the biotechnology company. This move comes amid a broader range of analyst activity, with multiple firms issuing both positive and negative ratings in…
AInvest Wire · 6d agoExelixis Inc: Jefferies raises target price to $70 from $66
Jefferies has revised its price target for Exelixis Inc (NASDAQ: EXEL) to $70 from $66, reflecting an increased outlook for the biopharmaceutical company. The adjustment follows an evaluation of recent developments in Exelixis’ pipeline and market dynamics. The firm’s updated target suggests a…
AInvest Wire · Oct 7, 2026Exelixis Inc: Leerink Partners assumes coverage with market perform rating; target price $55
Leerink Partners has initiated coverage of Exelixis Inc. (NASDAQ:EXEL), assigning the stock a "Market Perform" rating and setting a price target of $55 per share. This move follows recent analyst activity, including upgrades and downgrades from other firms, reflecting ongoing evaluation of the…
AInvest Wire · Oct 5, 2026RyvU Therapeutics - Planned implementation period for project is 58 months
Ryvu Therapeutics has outlined a comprehensive development plan for its ongoing oncology research and clinical programs, with a projected implementation period of 58 months. The company continues to advance its lead candidate, romaciclib (RVU120), a first-in-class selective CDK8/CDK19 inhibitor,…
AInvest Wire · Sep 18, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.